# MAPKeeper 301: HCP commentary report

> 138 verified statements (64 from clinicians verified by NPI or staff page) from 37 commentary sources · 12 findings · updated Nov 1, 2026

## Report

- Trial: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
- NCT ID: NCT07562152
- Registry: https://clinicaltrials.gov/study/NCT07562152
- Sponsor: Immuneering Corporation
- Phase: Phase 3
- Status: Recruiting
- Drugs tested: atebimetinib
- Indication: first-line metastatic pancreatic ductal adenocarcinoma
- Version: v1.0.0, edition 1
- Accepted: 2026-11-01
- Last checked: 2026-11-01
- Release hash: 2a10564f1473c802cc95037db711d481fdd9710a56c13f701316d609dd7390cc

## Counts

- HCP commentary sources screened: 89
- Sources cited by verified statements: 37
- Verified statements: 138
- From speakers with a confirmed clinical role (verified by the NPI registry or their own institution's staff page): 64
- Findings: 12
- Named people in screened sources (unnamed speakers and accounts not counted): 14
- Voices cited: 14
- Cited voices identity-verified: 8
- Organisational or shared accounts (not counted as people): 8

Counts describe the retained sources. They do not estimate how many HCPs hold a view.

## Abstract

MAPKeeper 301 compares atebimetinib plus modified gemcitabine/nab-paclitaxel (mGnP) with standard chemotherapy for overall survival in metastatic pancreatic ductal adenocarcinoma; discussion centers on randomized confirmation before adoption. The report cites three physicians, including one medical oncologist described in the source as involved in the trial; high-grade toxicity attribution remains unresolved. Can randomized survival, toxicity and patient-reported outcomes distinguish drug benefit from selection and subsequent care, and clarify which first-line patients value the trade-off? The sources reviewed for this edition place the earlier phase 2a atebimetinib plus mGnP results at ASCO 2026.

## Open Medical Affairs question

Can randomized survival, toxicity and patient-reported outcomes distinguish drug benefit from selection and subsequent-care effects while clarifying which first-line patients would value the trade-off?

Raised by the leading finding. The report shows what clinicians said and the sources behind it; it does not settle the question.

## Findings (titles)

- F1. The survival signal attracts enthusiasm, but randomized confirmation remains the adoption threshold
- F2. The OS–PFS disconnect generates competing explanations, not a settled mechanism
- F3. Favorable tolerability assessments coexist with high-grade toxicity and attribution uncertainty
- F4. Weight, quality of life and ability to receive later therapy are valued outcomes
- F5. The pulsatile MEK rationale is attractive, but its clinical application remains contested
- F6. The first-line comparison sits within several active chemotherapy choices and schedule-dependent toxicity trade-offs
- F7. Biomarker-agnostic enrollment does not make early molecular work-up optional in practice
- F8. Germline findings can favor a different initial regimen and a conditional maintenance sequence
- F9. Patient fitness and preferences can favor less treatment—or supportive care instead
- F10. RAS-directed competition raises sequencing questions and conflicting positioning arguments
- F11. Recruitment and access enthusiasm should not be mistaken for an efficacy update
- F_vogel_phase2a_context. A speaker's interest concerns the earlier phase 2a combination study

## What sits behind each finding

Counts describe what the report retained, not how many clinicians hold a view. A statement can support more than one finding.

| Finding | Statements | Passages | Sources | Named voices | Counterview | Limitations |
| --- | ---: | ---: | ---: | ---: | --- | ---: |
| F1 | 10 | 9 | 8 | 7 | recorded | 2 |
| F2 | 10 | 4 | 4 | 2 | recorded | 2 |
| F3 | 6 | 6 | 5 | 5 | recorded | 2 |
| F4 | 8 | 6 | 5 | 5 | recorded | 3 |
| F5 | 12 | 8 | 7 | 6 | recorded | 2 |
| F6 | 10 | 7 | 3 | 2 | recorded | 2 |
| F7 | 11 | 8 | 2 | 2 | recorded | 3 |
| F8 | 5 | 4 | 2 | 1 | none recorded | 2 |
| F9 | 6 | 4 | 2 | 1 | none recorded | 2 |
| F10 | 9 | 8 | 8 | 7 | recorded | 6 |
| F11 | 11 | 7 | 7 | 7 | recorded | 3 |
| F_vogel_phase2a_context | 1 | 2 | 2 | 1 | none recorded | 3 |

### What the statements are

| Finding | Views | Questions and uncertainty | Clinical experience | Comparisons | Restated results and context | Passages supporting | Passages giving context | Sources by kind | Feeds the Medical Affairs question |
| --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | --- | --- |
| F1 | 6 | 0 | 0 | 3 | 1 | 12 | 0 | 7 posts and articles, 1 podcast or video | yes |
| F2 | 4 | 3 | 0 | 2 | 1 | 13 | 0 | 4 posts and articles | yes |
| F3 | 5 | 0 | 0 | 0 | 1 | 6 | 0 | 4 posts and articles, 1 podcast or video | yes |
| F4 | 6 | 1 | 1 | 0 | 0 | 8 | 0 | 4 posts and articles, 1 podcast or video | yes |
| F5 | 6 | 0 | 3 | 0 | 3 | 13 | 0 | 6 posts and articles, 1 podcast or video | yes |
| F6 | 2 | 0 | 1 | 1 | 6 | 12 | 1 | 3 podcasts and video | yes |
| F7 | 7 | 2 | 0 | 1 | 1 | 12 | 0 | 2 podcasts and video | yes |
| F8 | 5 | 0 | 0 | 0 | 0 | 5 | 1 | 2 podcasts and video | yes |
| F9 | 5 | 0 | 0 | 0 | 1 | 6 | 0 | 2 podcasts and video | yes |
| F10 | 4 | 3 | 0 | 1 | 1 | 9 | 0 | 6 posts and articles, 2 podcasts and video | yes |
| F11 | 6 | 1 | 1 | 0 | 3 | 13 | 5 | 7 posts and articles | yes |
| F_vogel_phase2a_context | 1 | 0 | 0 | 0 | 0 | 2 | 0 | 2 posts and articles | no |

### Trial dimensions

- Primary endpoint: Overall Survival: F1 (8 shared claims), F2 (7 shared claims), F3 (1 shared claims), F5 (1 shared claims), F11 (1 shared claims)
- Secondary endpoints: F1 (2 shared claims), F2 (4 shared claims), F3 (1 shared claims), F4 (4 shared claims)
- Population and setting: F6 (2 shared claims), F7 (5 shared claims), F9 (4 shared claims), F10 (1 shared claims)
- The comparison: F1 (1 shared claims), F4 (1 shared claims), F6 (9 shared claims), F8 (1 shared claims), F9 (1 shared claims)
- Safety and tolerability: F1 (1 shared claims), F3 (5 shared claims), F4 (3 shared claims), F5 (1 shared claims), F6 (3 shared claims)
- Design and conduct: F1 (5 shared claims), F2 (3 shared claims), F5 (1 shared claims), F11 (4 shared claims)

## Sample findings

Paraphrased; the full report links each statement to its source.

### F2. The OS–PFS disconnect generates competing explanations, not a settled mechanism

A post on X asks whether the earlier cohort resembles MAPKeeper 301 participants and why overall survival diverges from progression-free survival and response.

The post author's clinical role is not stated in the sources reviewed for this edition.

Source: X thread, 2026-06-02.

### F7. Biomarker-agnostic enrollment does not make early molecular work-up optional in practice

A physician on YouTube asks how combined DNA/RNA sequencing compares with other testing methods for finding actionable alterations in metastatic pancreatic ductal adenocarcinoma.

The question concerns treatment planning, not a testing requirement established for MAPKeeper 301.

Source: YouTube video, 2026-07-14.

## What's inside

| Section | Items | Access |
| --- | ---: | --- |
| Findings with interpretation, counterviews and limits | 12 | Titles free |
| Detailed analysis | 12 sections | Paid |
| Verified statements with short source quotes and links | 138 | Paid |
| Trial aspects mapped | 11 | Free |
| Sources with links | 37 | Counts free |
| Speaker attribution for cited voices | 14 | Paid |

## Trial aspects

11 discussed · 0 no commentary found · 0 assessment incomplete.

| Aspect | Coverage | Statements | Sources |
| --- | --- | ---: | ---: |
| Primary endpoint: Overall Survival | discussed | 16 | 8 |
| Secondary endpoints | discussed | 11 | 5 |
| Population and setting | discussed | 11 | 2 |
| The comparison | discussed | 14 | 5 |
| Safety and tolerability | discussed | 11 | 6 |
| Design and conduct | discussed | 14 | 10 |
| Pulsatile MEK rationale and earlier clinical development | discussed | 14 | 9 |
| Molecular work-up and germline-directed treatment pathways | discussed | 23 | 2 |
| Fitness, treatment burden, preferences and supportive care | discussed | 6 | 2 |
| Post-progression fitness and sequencing with RAS-directed alternatives | discussed | 13 | 8 |
| Regional access, recruitment, follow-up and timing | discussed | 18 | 12 |

An aspect marked incomplete is a question the public commentary did not let us answer. We show it rather than hide it.

## Sources

| Channel | Screened | Cited |
| --- | ---: | ---: |
| X threads | 74 | 32 |
| Bluesky threads | 10 | 0 |
| LinkedIn posts | 2 | 2 |
| YouTube | 2 | 2 |
| Podcasts | 1 | 1 |

- Screened window: 2025-12-17 to 2026-10-30
- Cited window: 2026-01-07 to 2026-10-30
- Retrieved: 2026-11-01

Screened sources were retrieved for this trial. Cited sources back at least one verified statement and include primary sources used for context.

## The trial

From ClinicalTrials.gov.

- Title: A Phase 3 Randomized, Open-Label Study of Atebimetinib in Combination With the Modified Gemcitabine and Nab-Paclitaxel Regimen Versus the Standard Gemcitabine and Nab-Paclitaxel Regimen for the Treatment of Patients With Metastatic Pancreatic Ductal Pancreatic Adenocarcinoma Cancer (MAPKeeper 301)
- Registry: NCT07562152 (https://clinicaltrials.gov/study/NCT07562152)
- Study IDs: IMM1104-301
- Sponsor: Immuneering Corporation
- Design: Phase 3 · interventional, randomized, parallel, phase3
- Status: Recruiting
- Enrollment: 510 (estimated)
- Start: 2026-06-05 (actual)
- Primary completion: 2028-06 (estimated)
- Primary endpoint: Overall Survival (Up to approximately 2 years)
- Intervention: Atebimetinib (drug)
- Intervention: GnP (drug)
- Intervention: mGnP (drug)

## Scope and limits

This report does not judge efficacy, estimate HCP prevalence or consensus or give treatment advice.

- Discussion that does not name the trial may be missing from this edition.
- Not yet captured in this edition: a remark on first-line pancreatic cancer efficacy evidence and planned pivotal trial initiation.
- Not yet captured in this edition: a remark on the start of patient dosing in the pivotal metastatic pancreatic cancer trial.
- Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.
- 103 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.
- Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.
- The sources reviewed do not represent all HCPs or all public discussion. Some relevant passages were not fully assessed, and unnamed references or wording variants may be missing; absence of a view is not evidence that nobody expressed it.
- The material mixes documented clinician commentary, authors whose clinical roles are not established, company statements and investment-oriented interpretations. These categories cannot be pooled into an HCP consensus.
- Similar posts, reposts and substantially overlapping educational videos are not independent opinions. A confirmed identifier or professional association does not increase the truth or evidentiary weight of a view.
- No exact-trial outcomes publication or protocol was available. Formal eligibility detail, amendments and regulatory assertions could not be independently checked from those documents.
- Most numerical efficacy and safety discussion concerns earlier-phase studies, with historical comparators and differing cohorts, follow-up or reported values. It must not be presented as MAPKeeper 301 results.
- Some July educational-video comments have no identified speaker. Attribution in a separate upload does not establish who spoke those passages.
- Accounts differ in response estimates, safety attribution and anticipated trial timing. The report preserves those differences rather than choosing a preferred version.
- Approval characterizations and unusual drug names are preserved as the authors expressed them. They are not independently confirmed regulatory facts.
- Mechanistic explanations for weight preservation, post-progression survival and failures of other development programs remain attributed hypotheses, not established causal findings.

How reports are built and checked: https://www.erudio.com/methods

## Editions and corrections

- v1.0.0, accepted 2026-11-01: current edition

Last checked for new commentary 2026-11-01. No corrections. Versions follow semver: a new or changed finding is a minor version, more evidence without a material change is a patch.

## Offer

- Size: Focused (138 verified statements)
- Current edition: $750. A purchase starts a check for new commentary and any newer edition follows at no charge
- 3 months of weekly updates: $1,300
- 6 months of weekly updates: $1,900
- 12 months of weekly updates: $2,600
- Optional identity linkages (12-month updates only, product updates-12-identities; speakers are named and described in every report): NPI and other verified IDs at $15 per identity-verified person in the edition at purchase (8 now), at most $750; people verified later in the term at no charge
- Pricing: https://www.erudio.com/pricing
- Buy now (card, through Stripe): https://www.erudio.com/reports/mapkeeper-301-nct07562152
- Agents: POST https://www.erudio.com/api/orders with {"report": "mapkeeper-301-nct07562152", "product": "edition" | "updates-3" | "updates-6" | "updates-12" | "updates-12-identities", "buyer_email": "...", "licence_key": "<your key, if you hold one>"}; it returns a payment link for your user (and a pay_url your own MPP or x402 payment client can pay over HTTP 402, when offered), and once paid the status_url returns your license key. Send the same key with every later order so all reports sit on one key. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST https://www.erudio.com/api/keys/recover) sends it again
- Talk to Audun Utengen and Tom Lee (invoice, PO, questions): https://www.erudio.com/contact?report=mapkeeper-301-07562152

## Cite

Erudio Health. MAPKeeper 301 (NCT07562152): HCP commentary report. Edition 1, v1.0.0. Accepted Nov 1, 2026. https://www.erudio.com/reports/mapkeeper-301-nct07562152

## Machine access

- JSON: https://www.erudio.com/reports/mapkeeper-301-nct07562152.json
- Markdown: https://www.erudio.com/reports/mapkeeper-301-nct07562152.md
- MCP, no sign-in: https://mcp.erudio.com/free, tool `get_report_card` with `{"slug": "mapkeeper-301-07562152"}`